Author:
Akhavein Nima,Baum Marc M.,Gunawardana Manjula,Moss John A.,Calvez Sandrine,Remedios-Chan Mariana,Fanter Rob,Lenhard Steve,Rusk Samantha,Azzarano Leonard,McCoy Deborah,Jucker Beat,Johns Brian,Burke Matt,Velthuisen Emile
Abstract
AbstractGSK2838232 (GSK8232) is a second-generation maturation inhibitor (MI) developed for the treatment of HIV with excellent broad-spectrum virological profiles. The compound has demonstrated promising clinical results as an orally administered agent. Additionally, the compound’s physical and pharmacological properties present opportunities for exploitation as long-acting parenteral formulations. Despite unique design constraints including solubility and dose of GSK8232, we report on three effective tunable drug delivery strategies: active pharmaceutical ingredient (API) suspensions, ionic liquids, and subdermal implants. Promising sustained drug release profiles were achieved in rats with each approach. Additionally, we were able to tune drug release rates through a combination of passive and active strategies, broadening applicability of these formulation approaches beyond GSK8232. Taken together, this report is an important first step to advance long-acting formulation development for critical HIV medicines that do not fit the traditional profile of suitable long-acting candidates.
Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Prevailing against Pandemics by Putting People at the Centre—World AIDS Day Report 2020, UNAIDS, pp. 92 (2020).
2. Hendrix, C. W. HIV antiretroviral pre-exposure prophylaxis: Development challenges and pipeline promise. Clin. Pharmacol. Ther. 104, 1082–1097 (2018).
3. Diagnoses of HIV Infection in the United States and Dependent Areas, 2018 (Updated), Centers for Disease Control and Prevention (2018).
4. Estimated HIV Incidence and Prevalence in the United States 2010–2016, Centers for Disease Control and Prevention (2019).
5. Lykins, W. R., Luecke, E., Johengen, D., van der Straten, A. & Desai, T. A. Long acting systemic HIV pre-exposure prophylaxis: An examination of the field. Drug Deliv. Transl. Res. 7, 805–816 (2017).